Efficacy and safety of new direct oral anticoagulants in chronic kidney disease: AHA 2019 updated guidelines and review of the literature
{{output}}
Direct oral anticoagulants (DOACs) are the drug of choice for the treatment of atrial fibrillation-associated systemic embolism and reducing the risk of strokes in chronic kidney disease (CKD) patients. DOACs have fewer drug-to-drug interactions as well as few... ...
